Pasithea Therapeutics Corporation has released an investor presentation detailing its current corporate overview and ongoing projects. The presentation provides insights into the company's pipeline developments, including the clinical trial progress of its product candidate, PAS-004, for advanced cancer patients. It highlights the company's focus on advancing its clinical and preclinical candidates and discusses the design and conduct of its ongoing Phase 1 clinical trial. The presentation also addresses the company's plans for future operations, including the pursuit of new indications and the filing of regulatory documents. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.